cox 189 has been researched along with oxybutynin in 3 studies
| Studies (cox 189) | Trials (cox 189) | Recent Studies (post-2010) (cox 189) | Studies (oxybutynin) | Trials (oxybutynin) | Recent Studies (post-2010) (oxybutynin) |
|---|---|---|---|---|---|
| 163 | 49 | 47 | 2,607 | 619 | 1,670 |
| Protein | Taxonomy | cox 189 (IC50) | oxybutynin (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.5951 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.027 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.002 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0032 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0035 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0027 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.5951 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.6 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.4288 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.792 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.0855 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.0242 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for cox 189 and oxybutynin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for cox 189 and oxybutynin
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |